<DOC>
	<DOCNO>NCT00120419</DOCNO>
	<brief_summary>The purpose study evaluate whether mycophenolate mofetil ( MMF ) treat chronic hyperactivation immune system ( partly ) prevent decrease CD4+ T-cell count chronically HIV-1 infect patient treated antiretroviral therapy ( ART ) . The researcher also want know effect treatment MMF plasma HIV-1 RNA ; progression disease ( occurrence AIDS define event reach indication start ART ) ; safety treatment MMF patient group .</brief_summary>
	<brief_title>Mycophenolate Mofetil Antiretroviral Naïve Patients 2 ( MAN2 Study )</brief_title>
	<detailed_description>*Background : During chronic HIV-1 infection immune system chronically hyperactivated . This hyperactivation consider main cause CD4+ T-cell loss . Furthermore , HIV replicate efficiently activate CD4+ T-cells . In study try inhibit activation immune system mycophenolate mofetil ( MMF ) . Previous study HIV-1 infect patient treat MMF addition antiretroviral treatment ( ART ) show additional effect , compare ART alone . In study MMF use without antiretroviral medication . *Objectives : Primary objective study evaluation effect MMF chronic hyperactivation immune system decrease CD4+ T-cell count chronically HIV-1 infect patient treated antiretroviral therapy ( ART ) . Secondary objective include evaluation effect MMF plasma HIV-1 RNA ; progression disease/ reach indication start ART ; safety treatment MMF patient group . *Study Design : This multi center , randomize , open-label study , patient randomize treatment mycophenolate mofetil ( MMF ) 500 mg BID 48 week versus treatment . In subgroup 20 patient ( `` immunology group '' , first 20 patient AMC hospital , Amsterdam , Netherlands ) number additional immunological measurement perform . The study duration 60 week ( 48 week treatments 1 additional visit 12 week cessation treatment ) . *Study Population : Potential participant adult chronically HIV-1 infected patient , never treat ART accord present criterion need treat . CD4+ T lymphocyte count &gt; 250 &lt; = 450 * 106/L , plasma HIV-1 RNA ( viral load ) &lt; 10.000 copies/ mL . *Intervention : Patients randomize ( 1:1 ) mycofenolate mofetil ( MMF ) 500 mg BID versus treatment . *Endpoints : Primary endpoint change time ( baseline - week 48 ) CD4+ T cell count peripheral blood lymphocyte ( PBMC ) activation marker . Secondary endpoint change time ( baseline - week 48 ) plasma HIV-1 RNA , time reach indication start ART ( separate three group : 1. two consecutive measurement CD4+ T cell count 250 * 106 cells/ L least 4 week interval ; 2. occurrence CDC class B C event ; 3. reason ) ; safety data .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<criteria>Patient ≥ 18 year age ; Patient proven HIV1 infection ( antibody HIV1 detectable plasma HIV1 RNA measure first time least 6 month prior inclusion ) ; Patient HIV1 treatment naïve ; CD4+ T lymphocyte count &gt; 250 &lt; = 450 * 106/L ; No sign history AIDS defining event ; No use medication might possibly influence effect MMF ; Male ; female sex willingness practice effective contraception study . Plasma HIV1 RNA &lt; 10.000 copies/ mL ; Autoimmune disease ; Active hepatitis B C virus infection ; Other chronic disease ; Recent infectious disease HIV1 ; Treatment immunomodulatory antiinflammatory medication past 6 month ; For female patient : pregnancy lactation ; Any condition , illness use medication accord investigator compatible use study medication could interfere evaluation require study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2006</verification_date>
	<keyword>HIV-1 infection</keyword>
	<keyword>immunomodulatory therapy</keyword>
	<keyword>Treatment Naive</keyword>
</DOC>